MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, UNCY had $8,173K increase in cash & cash equivalents over the period. -$6,249K in free cash flow.

Cash Flow Overview

Change in Cash
$8,173K
Free Cash flow
-$6,249K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Gross proceeds from secondary pu...
    • Change in fair value of warrant ...
    • Accounts payable and accrued lia...
    • Others
Negative Cash Flow Breakdown
    • Net income (loss)
    • Purchases of marketable securiti...
    • Prepaid expense and other curren...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
-12,823 -14,668 -6,010 -5,877
Depreciation expense
8 10 10 14
Loss on disposal of assets
-18 ---
Stock-based compensation expense
754 777 730 1,134
Change in fair value of warrant liability
4,780 7,768 -1,067 -8,722
Amortization of operating lease right of use asset
203 141 138 259
Amortization of investments in marketable securities
12 ---
Prepaid expense and other current assets
1,267 98 394 2,392
Accounts payable and accrued liabilities
2,285 -1,814 775 -1,466
Operating lease liability
-211 -148 -144 -273
Net cash used in operating activities
-6,241 -8,032 -5,962 -17,323
Purchases of marketable securities
5,149 12,071 --
Purchases of property and equipment
8 0 2 22
Realized gain on marketable securities
-2 ---
Issuance costs related to issuance of series b-1 preferred stock
---0
Net cash used in investing activities
-5,155 -12,071 -2 -22
Payments on financed insurance policies
-0 1 211
Proceeds from exercise of warrants
-0 0 1,496
Proceeds from issuance of series b-1 preferred stock
---0
Dividends on preferred stock
---0
Gross proceeds from secondary public offering
20,174 6,811 27,147 12,624
Commissions paid on secondary public offering
605 205 814 379
Net cash provided by financing activities
19,569 6,606 26,332 13,530
Net increase (decrease) in cash and cash equivalents
8,173 -13,497 20,368 -3,815
Cash and cash equivalents at the beginning of the period
29,198 42,695 26,142 -
Cash and cash equivalents at the end of the period
37,371 29,198 42,695 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Gross proceeds fromsecondary public offering$20,174K Net cash provided byfinancing activities$19,569K Canceled cashflow$605K Net increase(decrease) in cash and cash...$8,173K Canceled cashflow$11,396K Commissions paid onsecondary public offering$605K Change in fair value ofwarrant liability$4,780K Accounts payable andaccrued liabilities$2,285K Stock-based compensationexpense$754K Amortization of operatinglease right of use...$203K Loss on disposal ofassets-$18K Amortization of investmentsin marketable...$12K Depreciation expense$8K Realized gain onmarketable securities-$2K Net cash used inoperating activities-$6,241K Net cash used ininvesting activities-$5,155K Canceled cashflow$8,060K Canceled cashflow$2K Net income (loss)-$12,823K Purchases of marketablesecurities$5,149K Purchases of property andequipment$8K Prepaid expense andother current assets$1,267K Operating lease liability-$211K

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics, Inc. (UNCY)